Immunome (IMNM) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving Immunome (IMNM) right now is Varegacestat FDA decision and launch: The submitted NDA for varegacestat in desmoid tumors is the single largest near-term driver. Revenue (FY2025) is ~$7M. If that keeps playing out, the setup is favourable; the risk to it is as a clinical-stage biotech, Immunome is exposed to substantial binary risk: the FDA could delay, restrict, or reject varegacestat, and any label or safety concern would materially reset the stock. No one can predict where IMNM trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Immunome (IMNM) higher?
1. Varegacestat FDA decision and launch
The submitted NDA for varegacestat in desmoid tumors is the single largest near-term driver. Strong Phase 3 RINGSIDE data (roughly 84% reduction in progression-or-death risk and a ~56% objective response rate) supports the filing, and an approval would turn Immunome into a commercial-stage company. The launch would enter a market where an approved oral competitor already exists.
2. ADC and radiotherapy pipeline
Beyond the lead drug, Immunome is building a pipeline of antibody-drug conjugates and targeted radiotherapies, including IM-1021 (ROR1 ADC), IM-3050 (FAP radiotherapy), and IM-1617. Management has guided to additional IND filings (IM-1340 and IM-1335) through 2026 and beyond. Investors increasingly frame varegacestat as the beachhead and the ADC platform as the longer-term thesis.
3. Strong balance sheet and runway
Cash and equivalents of roughly $582.7 million as of March 31, 2026 give Immunome runway into 2028, which reduces near-term financing pressure. That capital lets the company fund a potential commercial launch and advance multiple clinical programs at once. It does not, however, remove dilution risk if the company raises again to fund growth.
4. Desmoid tumor market opportunity
Desmoid tumors are a rare, locally aggressive soft-tissue condition with limited systemic options, giving a differentiated oral therapy a defined commercial niche. Immunome positions varegacestat on efficacy and tolerability against the incumbent. Success here could also validate the gamma secretase mechanism for adjacent indications.
What could weigh on IMNM?
As a clinical-stage biotech, Immunome is exposed to substantial binary risk: the FDA could delay, restrict, or reject varegacestat, and any label or safety concern would materially reset the stock. The company has minimal product revenue and posts recurring net losses (a net loss of roughly $53.8 million in Q1 2026), so it depends on its cash balance and, potentially, future capital raises that could dilute shareholders. Even with approval, commercial uptake is uncertain because an established oral competitor already serves the desmoid market. Pipeline candidates are early and most drug programs fail in development. The shares are volatile and can move sharply on single trial, regulatory, or insider-selling headlines.
Where IMNM trades today
A forecast starts from where the stock actually is. These are IMNM's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for IMNM as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a IMNM forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the IMNM guide and whether IMNM is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the IMNM outlook
The bottom line: what is driving Immunome (IMNM) is Varegacestat FDA decision and launch, with revenue (fy2025) at ~$7M. If that keeps playing out the setup is favourable; the risk is as a clinical-stage biotech, Immunome is exposed to substantial binary risk: the FDA could delay, restrict, or reject varegacestat, and any label or safety concern would materially reset the stock. No one can predict the price, so treat any IMNM forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around IMNM with Walnut
Use Immunome as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Immunome (IMNM)?
+
No one can reliably predict where IMNM will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Immunome higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive IMNM higher?
+
The main growth drivers are Varegacestat FDA decision and launch; ADC and radiotherapy pipeline; Strong balance sheet and runway. Whether they play out is the real question, not a guaranteed path.
What are the risks to IMNM?
+
As a clinical-stage biotech, Immunome is exposed to substantial binary risk: the FDA could delay, restrict, or reject varegacestat, and any label or safety concern would materially reset the stock. The company has minimal product revenue and posts recurring net losses (a net loss of roughly $53.8 million in Q1 2026), so it depends on its cash balance and, potentially, future capital raises that could dilute shareholders. Even with approval, commercial uptake is uncertain because an established oral competitor already serves the desmoid market. Pipeline candidates are early and most drug programs fail in development. The shares are volatile and can move sharply on single trial, regulatory, or insider-selling headlines.
Will IMNM stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Immunome's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is IMNM a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the IMNM "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.